



Drug Name: Hetlioz (tasimelteon)
Date: 7/2018

Drug Name:	Hetlioz (tasimelteon)
Required Medical Information:	<p>FDA Approved Indication</p> <ul style="list-style-type: none"> The treatment of non-24-hour sleep-wake disorder. <p>Requirements for Approval - Initial</p> <ul style="list-style-type: none"> The patient has a diagnosis of non-24-hour sleep-wake disorder The patient has a diagnosis of total blindness in both eyes (e.g. nonfunctioning retinas) The patient is unable to perceive light in either eye The patient is not currently receiving Hetlioz <p>Requirements for Approval – Renewal</p> <ul style="list-style-type: none"> The patient has a diagnosis of non-24-hour sleep-wake disorder The patient has a diagnosis of total blindness in both eyes (e.g. nonfunctioning retinas) The patient is unable to perceive light in either eye The patient is not currently receiving Hetlioz The patient meet AT LEAST ONE of the following criteria: A) The patient is experiencing increased total nighttime sleep, OR B) The patient is experiencing decreased daytime nap duration
Coverage duration:	<p>Initial Approval: 3 months</p> <p>Renewal Approval: 12 months</p>